restor3d Completes Acquisition of Conformis
05 Settembre 2023 - 2:18PM
restor3d, Inc. and Conformis, Inc. announced today that restor3d
has completed its previously announced acquisition of Conformis
following the approval of Conformis’ stockholders at a special
meeting held on August 31, 2023. In connection with the completion
of the acquisition, shares of Conformis’ common stock ceased
trading on the NASDAQ prior to the opening of the NASDAQ on
September 5, 2023.
“We are extremely excited to complete this
important transaction and look forward to leveraging our combined
portfolio to deliver personalized orthopedic solutions for the
whole human body,” said J. Kurt Jacobus, CEO of restor3d. “With the
addition of Conformis to the organization, we see tremendous
opportunity to deliver clinically differentiated and cost-effective
solutions across the orthopedic landscape, including shoulder, foot
& ankle, spine, and large joints such as knees and hips. We
have mapped out a product roadmap that will deepen and extend our
offerings across the body, providing surgeons and patients with the
personalized device solutions they deserve.”
restor3d manufactures a full range of personalized
orthopedic devices from patient-specific, to patient-matched, as
well as a range of associated ancillary products. With existing
expertise in 3D printing of osseointegrative biomedical materials,
biomechanics modeling, artificial-intelligence-based planning and
design automation tools, the addition of Conformis propels the
scalable future of best-in-class personalized device solutions to
present day.
About restor3d, Inc.restor3d is a
world leader in patient specific musculoskeletal implants and
driven by the belief that every patient deserves personalized care.
The company holds proprietary expertise in 3D printing of
osseointegrative materials, AI-based planning and design automation
tools, and digital health solutions to provide seamless data-backed
care to optimize individual patient outcomes. Alongside its
customers, restor3d is reimagining the musculoskeletal
reconstruction landscape. More information is available
at www.restor3d.com.
Advisors Jones Day served as legal
counsel to restor3d. UBS Investment Bank served as financial
advisor to Conformis, and Hogan Lovells US LLP served as its legal
counsel.
Contacts Kurt JacobusChief
Executive Officer |
restor3dE: Kurt@restor3d.com
Grafico Azioni Conformis (NASDAQ:CFMS)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Conformis (NASDAQ:CFMS)
Storico
Da Mag 2023 a Mag 2024